Profile: Arena Pharmaceuticals Inc (ARNA.A)

ARNA.A on American Stock Exchange

1 Oct 2014
Price Change (% chg)

$-0.14 (-3.31%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Arena Pharmaceuticals, Inc. (Arena), incorporated on April 14, 1997, is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases, and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in preclinical development. In June 2012, the United States Food and Drug Administration (FDA) approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese.

The Company’s research and development programs also include GPR119 and earlier-stage programs that span several therapeutic areas. The three trials included in its BELVIQ Phase III development program are BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (Behavioral modification and Lorcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), which enrolled approximately 7,794.

In October 2012, the Company initiated a Phase I multiple dose clinical trial of APD811. In April 2013, the Company initiated a randomized, double-blind and placebo-controlled Phase I clinical trial of APD334. APD371 is the Company’s lead product, which is under preclinical development. GPR119 is a pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes. GPR119 is expressed in beta cells, which are located in the pancreas and responsible for secreting insulin in response to increases in blood glucose.

The Company competes with Roche Group, GlaxoSmithKline Consumer Healthcare, VIVUS Inc. and Orexigen Therapeutics, Inc.

Company Address

Arena Pharmaceuticals Inc

6154 Nancy Ridge Drive
SAN DIEGO   CA   92121
P: +1858.4537200
F: +1858.4537210

Search Stocks